Media coverage about Orthofix International (NASDAQ:OFIX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Orthofix International earned a news sentiment score of 0.23 on Accern’s scale. Accern also gave media headlines about the medical device company an impact score of 46.514007204985 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s rankings:
- 38th Supplemental Approval for Orthofix’s Physio-Stim (ryortho.com)
- Orthofix International (OFIX) Downgraded by BidaskClub to Sell (americanbankingnews.com)
- Active-Investors: Blog Exposure – FDA Cleared Orthofix International’s G-Beam Fusion Beaming System (finanznachrichten.de)
- Blog Exposure – FDA Cleared Orthofix International’s G-Beam Fusion Beaming System (finance.yahoo.com)
- Orthofix receives FDA clearance for its G-Beam Fusion Beaming System (dotmed.com)
NASDAQ OFIX opened at $58.78 on Friday. The firm has a market cap of $1,058.84, a PE ratio of 178.13, a price-to-earnings-growth ratio of 3.23 and a beta of 0.24. Orthofix International has a twelve month low of $36.10 and a twelve month high of $61.00.
Several brokerages have issued reports on OFIX. TheStreet upgraded Orthofix International from a “c+” rating to a “b” rating in a report on Tuesday, March 20th. BidaskClub upgraded Orthofix International from a “hold” rating to a “buy” rating in a report on Friday, March 16th. SunTrust Banks upped their target price on Orthofix International to $67.00 and gave the company a “buy” rating in a report on Monday, March 5th. ValuEngine upgraded Orthofix International from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Finally, Gabelli restated a “buy” rating on shares of Orthofix International in a report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $57.42.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://baseballnewssource.com/2018/03/30/orthofix-international-ofix-earning-somewhat-favorable-news-coverage-analysis-shows/1973538.html.
Orthofix International Company Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.